HER2 Heterogeneity Impacts Response Rates in HER2-Positive Breast Cancer

Leggi l'articolo originale


A trial presented at ASCO 2019 found HER2 heterogenity can impact response rates to some treatments in HER2-positive breast cancer patients.

Lascia un commento